Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch in
吉利德科学先期投入16.8亿美元，押注Ouro Medicines的自身免疫项目，预计加拉帕戈斯将参与出资

Gilead Sciences is set to enter the T cell engager space in an unusual — perhaps even unprecedented — deal arrangement that involves the pharma budgeting about $1.68 billion upfront to buy Ouro Medicines and for Galapagos to do early work on the candidate.
吉利德科学将以一种不同寻常、甚至可能前所未有的交易安排切入T细胞连接子领域：该制药公司计划先行拨出约16.8亿美元的预付款收购Ouro Medicines，并由加拉帕戈斯负责该候选药物的早期研发工作。